Science

May 20, 2025, 09:15

Myeloma Paper of the Day, May 20th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Single center study of dual BCMA/GPRC5D bispecific CAR T finds a somewhat disappointing 44.4% (4/9) CR rate, 1-year OS and PFS rates of 60% and 63%, respectively, though all pts had EMD at baseline.”

Title: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

Authors: Hao Yao, Shi-hui Ren, Lin-hui Wang, Ming-qiang Ren, Jiao Cai, Dan Chen, Ying He, Si-han Lai, Bai-tao Dou, Meng-jiao Li, Yan-ling Li, Ya-li Cen, Alex H. Chang, Yi Su, Ling Qiu, Fang-yi Fan.

You can read the Full Article in Journal of Hematology and Oncology.

More posts featuring Robert Orlowski.

Alex H. Chang Bai-tao Dou cancer Dan Chen Fang-yi Fan Hao Yao Jiao Cai Lin-hui Wang Ling Qiu Meng-jiao Li Ming-qiang Ren Myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski RRMM Shi-hui Ren Si-han Lai Ya-li Cen Yan-ling Li Yi Su Ying He

Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC